They found that 25 miRNAs between well-poorly differentiated tumors, eight miRNAs before and after of the chemotherapy, three miRNAs between favorable and unfavorable histology, four miRNAs between neuroblastoma and ganglioneuroma, seven miRNAs between low and middle risk, one miRNA between middle and high risk, 14 miRNAs between low and high risk were differently expressed. KEGG pathway analysis revealed that these miRNAs mainly targeted the cancer pathway. After comparing the clinical data and all microRNAs, the most marked difference was seen in miR-132 and miR-490. The highest fold change was detected in miR-98-5p between the tissues of high- and low-risk patients.
This study provides microRNA expression profiles of neuroblastoma patients’ tissue with different clinical, histological grade, differentiation, and treatment status, which could be informative for new therapies targeting microRNAs.
Heat-map of differentially expressed miRNA in comparison of poorly (P)-well (W) differentiated groups (p < 0.01). The analysis shows relative fluorescence from green (2-fold reduction) to red (2-fold increase) of each sample